Relaxin does not improve Angiotensin II-induced target-organ damage.
Relaxin is a corpus-luteum produced protein hormone with vasodilatatory, anti-fibrotic, and angiogenic properties that are opposite to angiotensin (Ang) II. We investigated whether or not relaxin ameliorates Ang II-induced target-organ damage. We used double transgenic rats harboring both human reni...
Main Authors: | Nadine Haase, Julianna Rugor, Lukasz Przybyl, Fatimunnisa Qadri, Dominik N Müller, Ralf Dechend |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24710077/?tool=EBI |
Similar Items
-
Relaxin Treatment in an Ang-II-Based Transgenic Preeclamptic-Rat Model.
by: Nadine Haase, et al.
Published: (2016-01-01) -
Prevention and Reversal by Enalapril of Target Organ Damage in Angiotensin II Hypertension
by: Caroline Rugale, et al.
Published: (2005-09-01) -
Targeting the Relaxin Pathway for Liver Disease Treatment
by: Robert G. Bennett
Published: (2018-05-01) -
Relaxin as a Therapeutic Target for the Cardiovascular Complications of Diabetes
by: Hooi Hooi Ng, et al.
Published: (2018-05-01) -
Angiotensin II induced inflammation in the kidney and in the heart of double transgenic rats
by: Haller Hermann, et al.
Published: (2002-01-01)